Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Encephalitis - Overview
Encephalitis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Encephalitis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Encephalitis - Companies Involved in Therapeutics Development
CEL-SCI Corp
F. Hoffmann-La Roche Ltd
Knight Therapeutics Inc
Sage Therapeutics Inc
Encephalitis - Drug Profiles
Amphotericin B sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CEL-1000 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cerium dioxide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
miltefosine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ocrelizumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pneumococcal (13-valent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pneumococcal (23-valent) vaccine - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Polyglactin 370 for Encephalitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAGE-718 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Encephalitis - Dormant Projects
Encephalitis - Product Development Milestones
Featured News & Press Releases
Jul 06, 2018: Knight receives adverse notice of reassessment from CRA
Jun 28, 2017: FDA Grants Profounda Orphan Drug Desigtion for treatment of Granulomatous Amebic Encephalitis (GAE) with Miltefosine
Dec 17, 2016: Profounda receives FDA orphan-drug desigtion for the Treatment of Primary Amebic Meningoencephalitis (PAM) with Miltefosine
Aug 24, 2016: Orlando patient survives Primary Amebic Meningoencephalitis using Profoundas drug Impavido (miltefosine)
Dec 15, 2015: U.S. Issues Patent on Corifungin
Feb 26, 2013: tiol Institutes of Health Supports Acea’s Research
Aug 22, 2011: Dr. James McKerrow, efficacy of Corifungin vs. egleria
Aug 22, 2011: FDA Grants 2nd Orphan drug desigtion
Feb 10, 2010: Dr. Jose Vazquez presents poster at ICAAC
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


Number of Products under Development for Encephalitis, H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products by Targets, H2 2019
Number of Products by Stage and Targets, H2 2019
Number of Products by Mechanism of Actions, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Routes of Administration, H2 2019
Number of Products by Stage and Routes of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019


List of Tables


Number of Products under Development for Encephalitis, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Encephalitis - Pipeline by CEL-SCI Corp, H2 2019
Encephalitis - Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Encephalitis - Pipeline by Knight Therapeutics Inc, H2 2019
Encephalitis - Pipeline by Sage Therapeutics Inc, H2 2019
Encephalitis - Dormant Projects, H2 2019